Overview

• The case is filed in the Southern District of New York as Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500.
• The putative class covers purchasers of MoonLake common stock from March 10, 2024 through September 29, 2025.
• Complaints allege MoonLake misrepresented sonelokimab’s prospects by overstating advantages over BIMZELX despite overlapping IL-17A/IL-17F targets and no proven Nanobody-derived clinical benefit.
• Plaintiffs tie the claims to MoonLake’s September 28 disclosure of 16-week Phase 3 VELA results that were not competitively efficacious versus BIMZELX and to a stock drop of nearly 90%.
• Robbins Geller, Bronstein Gewirtz & Grossman, Rosen Law Firm, and Bleichmar Fonti & Auld have issued notices and are soliciting investors on a contingency-fee basis, with participation in any recovery not contingent on serving as lead plaintiff.